BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The trial is being conducted in the United Kingdom (UK), in partnership with the UK Government’s Vaccines Taskforce, and is expected to enroll

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.

Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial In an interim analysis, CheckMate -274 met primary endpoints of disease-free survival in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% Opdivo has now demonstrated clinically meaningful efficacy in the adjuvant treatment of

Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its fourth quarter an

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 11, 2020, the Compensation Committee of the Board of Directors approved “inducement” grants to 30 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle employees, in aggregate, to purchase up to 173,000 shares of common stock and receive

The COVID-19 pandemic and recent racial turmoil have brought to the national forefront systemic racial and social inequities that create heath disparities that devastate families and communities of color throughout the U.S.

Today, Maryland Governor Larry Hogan and Dr. Michelle McMurry-Heath, President & CEO of Biotechnology Innovation Organization (BIO), joined Novavax President & CEO Stanley Erck to discuss the importance of the biotechnology sector in Maryland, the industry’s efforts to address COVID-19, and progress being made by Novavax to develop a vaccine for the deadly virus

Community Health Centers and the nearly 30 million patients they serve have a temporary reprieve from a new regulation implementing the President’s Executive Order around insulin and EpiPens. The Office of Management and Budget (OMB) has revised the regulation from an Interim Final Rule to a Proposed Rule, signaling that the pub

Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it has initiated a process to optimize the development plan for Rabeximod.

Today, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration took actions to help provide safe, effective, and more affordable drugs